Dare Bioscience, Inc.
No enriched coverage for $DARE in the last 7 days.
No SEC Form 4 filings for $DARE in the last 30 days.
See all $DARE insider activity →Dare Bioscience, Inc. (DARE) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Exhibit 99.1 Daré Bioscience Announces Pricing of $6.0 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules San Diego, August 14, 2026 (GLOBE NEWSWIRE) — Daré Bioscience, Inc. (Nasdaq: DARE), a purpose-driven health biotech company solely focused on closing
Dare Bioscience, Inc. (DARE) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Daré Bioscience Reports Second Quarter 2026 Results and Highlights Commercial Inflection as Multi-Product Women’s Health Strategy Advances Company launches Flora Sync LF5™, the company’s first directly commercialized product, began generating revenue in July DARE to
Daré Bioscience (NASDAQ: DARE) said it launched a strategic collaboration with MyMenopauseRx, a menopause-focused telehealth platform. MyMenopauseRx will be featured as a telehealth partner for DARE’s DARE to PLAY Sildenafil Cream, offering menopause specialist access and related care options via insurance or cash. Shares opened lower Tuesday.
Recent DARE coverage spans financial news, corporate actions and earnings.
The 8-K indicates DARE has entered a material definitive agreement to sell securities (including pre-funded warrants and common warrants), which can be dilutive and may pressure near-term price.
The filing adds near-term commercialization catalysts (LF5 launch, Sildenafil Cream dispensing timeline) plus clinical pipeline updates (Ovaprene Phase 3 interim, DARE-HPV Phase 2 initiation).
The deal is a commercial distribution expansion that could modestly improve access and conversion, but it does not provide financial targets or near-term guidance.
First consumer product launch (no prescription, $49/box) is a tangible commercialization step that can change near-term revenue expectations and sentiment.
The 8-K discloses shareholder approval of a larger equity incentive pool, which can affect dilution expectations and equity-overhang sentiment.
alphai scores every news story that mentions DARE with an AI model for sentiment and relevance, and aggregates insider trades from Dare Bioscience, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Dare Bioscience, Inc. (DARE) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Exhibit 99.1 Daré Bioscience Announces Pricing of $6.0 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules San Diego, August 14, 2026 (GLOBE NEWSWIRE) — Daré Bioscience, Inc. (Nasdaq: DARE), a purpose-driven health biotech company solely focused on closing
3 min readDare Bioscience, Inc. (DARE) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Daré Bioscience Reports Second Quarter 2026 Results and Highlights Commercial Inflection as Multi-Product Women’s Health Strategy Advances Company launches Flora Sync LF5™, the company’s first directly commercialized product, began generating revenue in July DARE to
7 min readDaré Bioscience (NASDAQ: DARE) said it launched a strategic collaboration with MyMenopauseRx, a menopause-focused telehealth platform. MyMenopauseRx will be featured as a telehealth partner for DARE’s DARE to PLAY Sildenafil Cream, offering menopause specialist access and related care options via insurance or cash. Shares opened lower Tuesday.
2 min readDaré Bioscience (NASDAQ: DARE) said its vaginal probiotic Flora Sync LF5 is now available for order via its DARE Health Hub, marking the company’s first direct-to-consumer product revenue. The product is priced at $49 per box (6 capsules, 2 courses) and is non-prescription. Daré also cited ongoing Phase 2 DARE-HPV and Phase 3 Ovaprene progress.
3 min readDare Bioscience, Inc. (DARE) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. dare-20260611 0001401914 FALSE 0001401914 2026-04-13 2026-04-13 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported):
3 min readDaré Bioscience reported a Q1 2026 net loss of approximately $3 million on revenue of $152,455, primarily from R&D services and royalties. The company highlighted upcoming revenue milestones in 2026 and 2027 from product launches like Flora Sync LF5 and DARE to PLAY, while also advancing its pipeline with positive interim Phase 3 results for Ovaprene and ARPA-H funded DARE-HPV. Daré aims to build a multi-product revenue profile to complement its grant funding and equity financings.
4 min readSAN DIEGO, Nov. 24, 2025 ( GLOBE NEWSWIRE ) -- Daré Bioscience, Inc. ( NASDAQ:DARE ) , a purpose-driven health biotech company solely focused on closing the gap in women's health between promising science and real-world solutions, today announced that it has received an approximately $3.6 ...
3 min readImage source: The Motley Fool.Thursday, Nov. 13, 2025 at 4:30 p.m. ETNeed a quote from a Motley Fool analyst? Email pr@fool.comContinue reading ...
4 min readDare Bioscience (DARE) delivered earnings and revenue surprises of +15.15% and -95.00%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
3 min readEvent to Explore What Makes DARE to PLAY™ a First-of-Its-Kind Topical Sildenafil Cream for Women, Review Supporting Clinical Data, and Discuss 503B Pathway to Commercial Availability, Expected Before Year-End Event to Explore What Makes DARE to PLAY™ a First-of-Its-Kind Topical Sildenafil Cream ...
3 min read
